AiON

Acute kidney injury (testosterone-related)

Adverse effect seen more frequently in the testosterone-treated group (2.3%) than with placebo (1.5%) in the TRAVERSE trial.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.